

Tuesday, February 22 10:30 AM – 12:00 PM Esplanade, Room 158 Malvern Panalytical

A Biophysical Toolbox To Predict and Assess the Stability of Biopharmaceuticals and Vaccines

The ability to characterize the stability of biotherapeutic products is crucial to the successful development of commercially successful and safe biopharmaceuticals. As a consequence, protein aggregation is recognized by regulatory agencies and the biopharmaceutical industry as a key quality attribute for biotherapeutic products. During this presentation we will introduce the origins and consequences of aggregation in biotherapeutics and examine strategies for predicting and quantifying aggregation in biopharmaceutical formulation development.

In addition to traditional protein-based therapeutics, we will also cover vaccine development and stability assessment. A vaccine is a biological preparation that provides active acquired immunity to an infectious disease using the causative agent or components of it, to act as antigen inducing antibody without inducing the actual disease. We will introduce vaccine development, address the key challenges associated with each development platforms and introduce the state of the art analytical and biophysical technology solutions.

Speakers

Matthew McGann, Pharma & Food Territory Manager, Malvern Panalytical Ronald Soriano, Applications Scientist, Pharma & Food, Malvern Panalytical